Last week, AcelRx Pharmaceuticals (NASDAQ:ACRX) presented results from its Phase 3 SAP302 trial for its pipeline drug ARX-04, designed to treat patients suffering …
AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) announced that the Company and its investigators will be presenting results from the Phase 3 SAP302 study of ARX-04 (sufentanil …
AcelRx Pharmaceuticals Inc (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, …
AcelRx Pharmaceuticals Inc (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today …
Abercrombie & Fitch Co. (NYSE:ANF) is down close to 12% in pre-market trading after the firm released disappointing 1Q:16 earnings this morning.
AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) announced that the Company and its investigators will be presenting Phase 3 SAP301 study results at Euroanaesthesia 2016, which is …
AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) reported that the Company will be presenting an evaluation of the cost of delivering IV opioids in the emergency department …
